Orphazyme didn't know buyer before negotiations began

US-based Kempharm, which is set to purchase embattled Orphazyme, was until negotiations began relatively unknown to the Danish firm, according to CEO Anders Vadsholt, who still calls this the best solution considering the firm’s current situation.

Photo: Orphazyme/PR

Orphazyme, a listed company in Denmark that has been restructuring since in March, did not have any superficial knowledge of its potentially new US-based owner, Kempharm, before entering negotiations.

”No one had had any direct contact with them in the past,” CEO of Orphazyme Anders Vadsholt tells MedWatch, adding that the two firms got in touch through networking.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs